Annovis Bio, Inc. (ANVS)

Annovis Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	19.53	10.55	5.75	28.38	45.69
Cash & Short-Term Investments	19.53	10.55	5.75	28.38	45.69
Cash Growth	85.11%	83.36%	-79.72%	-37.89%	465.79%
Other Current Assets	1.55	3.37	4.45	7.64	0.32
Total Current Assets	21.08	13.93	10.21	36.02	46
Total Assets	21.08	13.93	10.21	36.02	46
Accounts Payable	2.59	2.31	1.29	3.96	0.69
Accrued Expenses	1.04	1.58	2.99	3.74	0.82
Total Current Liabilities	3.64	3.88	4.28	7.7	1.51
Other Long-Term Liabilities	0.6	0.74	13.68	-	-
Total Long-Term Liabilities	0.6	0.74	13.68	-	-
Total Liabilities	4.23	4.62	17.96	7.7	1.51
Common Stock	0	0	0	0	0
Additional Paid-in Capital	180.55	144.16	102.51	82.38	73.22
Retained Earnings	-163.7	-134.85	-110.26	-54.05	-28.73
Shareholders' Equity	16.85	9.31	-7.75	28.32	44.49
Total Liabilities & Equity	21.08	13.93	10.21	36.02	46
Net Cash (Debt)	19.53	10.55	5.75	28.38	45.69
Net Cash Growth	85.11%	83.36%	-79.72%	-37.89%	465.79%
Net Cash Per Share	0.95	0.86	0.64	3.48	5.99
Book Value	16.85	9.31	-7.75	28.32	44.49
Book Value Per Share	0.82	0.76	-0.86	3.47	5.83
Tangible Book Value	16.85	9.31	-7.75	28.32	44.49
Tangible Book Value Per Share	0.82	0.76	-0.86	3.47	5.83

Updated Mar 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q